Urinary Infection in Pregnant Women with Urinary Infection

January 31, 2025 updated by: Mohamed Gamal M.fekry, Assiut University

Urinary Tract Infections in Patients with Threatened Preterm Labor

Urine analysis and culture in patients with threatened preterm labour

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

UTI is an infection of the kidneys, bladder, or urethra. Infectious cystitis is the most common type of UTI, which is caused by a bacterial infection of the bladder. Lifetime incidence of UTIs is 50% to 60% in adult women.UTIs are among the most common conditions encountered in primary care, hospitals, and extended care facilities . Total direct costs of UTI treatment (without cultures) have been estimated at US $25.5 billion annually.Despite an exceptionally high prevalence of bacteriuria in the population, these infections rarely cause significant renal damage.Sexual intercourse is the strongest risk factor. Any lifetime sexual activity and any sexual activity during the past year are strongly associated with recurrent UTI. Even the relatively small amounts of spermicide coating condoms increases the risk of UTI. Post-menopausal absence of oestrogen is a risk factor for UTIs. Topical oestrogen reduces UTIs in post-menopausal women; Oestrogenisation of the vaginal mucosa promotes lactobacilli colonisation, which reduces the presence of uropathogens and thus the risk of UTIs and is not recommended over the use of topical oestrogen therapy. Urinary incontinence and oestrogen supplementation have also been associated with UTI in older women, although the reasons for this are incompletely understood. positive family history of UTIs is associated with a two- to fourfold increase in risk of recurrent UTI . Bacteriuria occurs in the presence of indwelling or intermittent catheters, and asymptomatic bacteriuria does not require treatment. Gestational and pregestational diabetes are considered a more predominant risk factor in older women.

Study Type

Observational

Enrollment (Estimated)

224

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with threatened preterm labor

Description

Inclusion Criteria:

  • pregnant women with preterm labor

Exclusion Criteria:

  • renal disease Intrauterine fetal death

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Pregnant women with threatened preterm labour
Patients with UTI and preterm labour
Other: Urine analysis
Urine analysis and culture for Screening and diagnostic tools for UTI in pregnant women

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
percent of urinary tract infections in threatened preterm labor
Time Frame: 1 month
Percentage of women with threatened preterm labor diagnosed with urinary tract infection
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Investigators

  • Principal Investigator: Mohammed Seif al nasr, MBBCH, Women's Health Hospital Resident

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2024

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

January 1, 2027

Study Registration Dates

First Submitted

December 20, 2024

First Submitted That Met QC Criteria

December 27, 2024

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 31, 2025

Last Verified

December 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UTIP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Threatened Preterm Labour

Clinical Trials on Urine analysis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe